Pacira BioSciences (FRA:82P) Net Income (Continuing Operations): €12.6 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:82P Pacira BioSciences Inc FRA:82P
79 GF Score
Price €22.60
GF Value €25.12
! 7 Warning Signs
View Full Analysis

What is Pacira BioSciences Net Income (Continuing Operations)?

Pacira BioSciences FRA:82P 79 Net Income (Continuing Operations) is €12.6 Mil as of Jun. 2026. GuruFocus rates FRA:82P with a GF Score™ of 79/100 and a GF Value™ of €25.12. The stock has 7 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Pacira BioSciences's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was €4.0 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was €12.6 Mil.

Pacira BioSciences  (FRA:82P) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Pacira BioSciences Net Income (Continuing Operations) Related Terms

Pacira BioSciences Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Pacira BioSciences's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pacira BioSciences Net Income (Continuing Operations) Chart

Pacira BioSciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.15 15.02 38.47 -95.08 6.01

Pacira BioSciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.20 4.63 1.40 2.52 4.04
FRA:82P
79GF Score
Pacira BioSciences Inc FRA:82P
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pacira BioSciences Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €12.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of €12.6 Mil mean?
Pacira BioSciences (FRA:82P) has a Net Income (Continuing Operations) of €12.6 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Pacira BioSciences and its competitors.
Is Pacira BioSciences' Net Income (Continuing Operations) too high?
Pacira BioSciences' current Net Income (Continuing Operations) is €12.6 Mil. Overall, Pacira BioSciences has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Net Income (Continuing Operations) compare to AMPH and COLL?
Pacira BioSciences' Net Income (Continuing Operations) of €12.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Pacira BioSciences and its competitors. Pacira BioSciences's current Net Income (Continuing Operations) is €12.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Net Income (Continuing Operations) of €12.6 Mil. The stock's GF Value™ is €25.12, compared to a current price of €22.60 — trading 10% below its estimated fair value. The current Net Income (Continuing Operations) is €12.6 Mil. Pacira BioSciences' overall GF Score™ is 79/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Net Income (Continuing Operations) is €12.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pacira BioSciences (FRA:82P) Overvalued in 2026?

Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued. The current stock price of €22.60 is trading 10% below its estimated GF Value™ of €25.12.

Key valuation signals for FRA:82P:

  • Net Income (Continuing Operations): €12.6 Mil
  • GF Value™: €25.12 vs. price of €22.60 (10% below fair value)
  • GF Score™: 79/100 with 7 warning signs

No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pacira BioSciences Business Description

Other Exchanges PCRX:USA82P:Germany
Address 2000 Sierra Point Parkway, Suite 900, Brisbane, CA, USA, 94005
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
79GF Score

Get the complete analysis for FRA:82P

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.60
Price
€25.12
GF Value